Silvia Santana-Krímskaya

Dr. Silvia Santana-Krímskaya

Universidad Autónoma de Nuevo León (UANL), Facultad de Ciencias Biológicas, Laboratorio de Inmunología y Virología, P.O. Box 46 “F”, 66455, San Nicolás de los Garza, NL, México
orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 December 2018 in Immunopharmacology and Immunotoxicology
Verified
Journal Article
Closed access
UGUniversidad Autónoma de Nuevo León RFC UANL691126MK2, Uso de CFDI: gastos en general
Universidad Autónoma de Nuevo León RFC UANL691126MK2, Uso de CFDI: gastos en general
MMMoisés Armides Franco Molina
Moisés Armides Franco Molina
AHAlex Jesús Hernádez-Granados
Alex Jesús Hernádez-Granados
DTDIANA ZARATE TRIVIÑO
DIANA ZARATE TRIVIÑO
ECErika Evangelina Coronado-Cerda
Erika Evangelina Coronado-Cerda
CRCristina Rodríguez-Padilla
Cristina Rodríguez-Padilla
Exosomes secreted by tumor cells are a good source of cellular components that stimulate the immune response, such as alarmins (mRNA, tetraspanins (CD9, CD63, CD81), heat-shock proteins, major histocompatibility complex class I molecules) and tumor-associated antigens. These properties permit to pulsed dendritic cells in the immunotherapy for many cancers types. The aim of this study was to demonstrate the use of exosomes derived from canine transmissible venereal tumor (CTVT) as an antigen to pulsed dendritic cells and its administration in dogs with CTVT as treatment against this disease. From primary culture of CTVT cells the exosomes were isolated and characterized by scanning electron microscopy assay, dot blot and protein quantification. The monocytes of each patient were differentiated to dendritic cells (DC) and pulsed with CTVT exosomes (CTVTE). Phagocytosis, tumor size, populations of lymphocytes and IFN-γ levels were evaluated. The CTVTE showed a size around 90 nm. CD81, CD63, CD9 and Hsp70 were expressed. Monocytes showed an expression of 85.71% for CD14+, 12.3% for CD80+, 0.1% for CD83+ and 0.8% for DLA-II. In DC 5.1% for CD14+, 86.7% for CD80+, 90.1% for CD83+ and 92.6% for DLA-II and a phagocytosis of 63% was obtained by FITC-Dextran test. No side effects were observed in the experimental groups with our therapy. Tumor regression was of 100% at the seventh week, as well as an increase in the level of IFN-γ (142 pg/ml), and CD4+ (28%) and CD8+ (34%) cell percentage. These results have shown that DC pulsed with tumor exosomes induce regression of the TVT in dogs.

1 June 2020 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
SSSilvia Santana-Krímskaya
Silvia Santana-Krímskaya
MMMoisés Armides Franco Molina
Moisés Armides Franco Molina
DTDIANA ZARATE TRIVIÑO
DIANA ZARATE TRIVIÑO
HPHeriberto Prado-Garcia
Heriberto Prado-Garcia
PZPablo Zapata-Benavides
Pablo Zapata-Benavides
CRCristina Rodríguez-Padilla
Cristina Rodríguez-Padilla
In 1889, Steven Paget postulated the theory that cancer cells require a permissive environment to grow. This permissive environment is known as the tumor microenvironment (TME) and nowadays it is evident that the TME is involved in the progression and response to therapy of solid cancer tumors. Triple-negative breast cancer is one of the most lethal types of cancer for women worldwide and chemotherapy remains the standard treatment for these patients. IMMUNEPOTENT CRP is a bovine dialyzable leukocyte extract with immunomodulatory and antitumor properties. The combination of chemotherapy and IMMUNEPOTENT CRP improves clinical parameters of breast cancer patients. In the current study, we aimed to evaluate the antitumor effect of doxorubicin/cyclophosphamide chemotherapy plus IMMUNEPOTENT CRP and its impact over the tumor microenvironment in a triple-negative breast cancer murine model. We evaluated CD8+, CD4+, T regulatory cells, memory T cells, myeloid-derived suppressor cells, CD71+, innate effector cells and molecules such as α-SMA, VEGF, CTLA-4, PD-L1, Gal-3, IDO, IL-2, IFN-γ, IL-12, IL-6, MCP-1, and IL-10 as part of the components of the TME. Doxorubicin/cyclophosphamide + IMMUNEPOTENT CRP decreased tumor volume, prolonged survival, increased infiltrating and systemic CD8+ T cells and decreased tumor suppressor molecules (such as PD-L1, Gal-3, and IL-10 among others). In conclusion, we suggest that IMMUNEPOTENT CRP act as a modifier of the TME and the immune response, potentiating or prolonging anti-tumor effects of doxorubicin/cyclophosphamide in a triple-negative breast cancer murine model.

1 December 2018 in Research in Veterinary Science
Verified
Journal Article
Closed access
AHAlex Jesús Hernández-Granados
Alex Jesús Hernández-Granados
MMMoisés Armides Franco Molina
Moisés Armides Franco Molina
ECErika Evangelina Coronado-Cerda
Erika Evangelina Coronado-Cerda
PZPablo Zapata-Benavides
Pablo Zapata-Benavides
EGEdgar Mendoza Gamboa
Edgar Mendoza Gamboa
CRCristina Rodríguez-Padilla
Cristina Rodríguez-Padilla

Verified
Journal Article
Open access
PDF file
MMMoisés Armides Franco Molina
Moisés Armides Franco Molina
SSSilvia Santana-Krímskaya
Silvia Santana-Krímskaya
BCBaltazar Cortés-García
Baltazar Cortés-García
JSJorge Alejandro Sánchez-Aldana-Pérez
Jorge Alejandro Sánchez-Aldana-Pérez
OGOscar García-Jiménez
Oscar García-Jiménez
JKJorge R. Kawas
Jorge R. Kawas
Rabies is a fatal viral infection that causes enc ephalitis in warm-blooded animals, including humans. Dog-transmitted rabies is considered eradicated in Mexico; however, rabies is not being tested in livestock with neurological symptoms (one of the main manifestations of rabies disease). In this case report, we describe a rabies case in a white-tailed deer in the Santo Domingo ranch, in Catazajá, Chiapas, Mexico, where white-tailed deer are kept under captivity, and are meant for human consumption. This is the first report of a rabies case in white-tailed deer in Mexico. We also describe the challenges to obtain a rabies diagnosis and the lack of public health policies to ensure containment of the disease, as well as the lack of awareness among farmers in the area. One single confirmed case of rabies indicates that more animals are affected by the disease. The risk for human health and economical losses will remain unknown until rabies tests are routinely performed in animals that present neurological symptoms.

7 November 2020 in Journal of Nanomaterials
Verified
Journal Article
Open access
PDF file
ZTZaida Torres-Cavazos
Zaida Torres-Cavazos
MMMoisés Armides Franco Molina
Moisés Armides Franco Molina
SSSilvia Santana-Krímskaya
Silvia Santana-Krímskaya
CRCristina Padilla Rodríguez-Padilla
Cristina Padilla Rodríguez-Padilla
JKJorge R. Kawas
Jorge R. Kawas
DADiana Elisa Zamora Avila
Diana Elisa Zamora Avila
Our main focus was to evaluate the efficacy of silver and sodium dichloroacetate as dual-function agents to be used in melanoma treatment. This strategy is designed to increase the activity of these two compounds that affect DNA integrity and the mitochondria at different levels. Furthermore, we evaluated if the cell death mechanism induced by our treatments was immunogenic cell death. To evaluate antitumor efficacy, we assessed tumor volume and production of tumor necrosis factor-α, nuclear factor κ B (both by ELISA), and nitric oxide levels (Nitrate/Nitrite colorimetric assay kit); for immunogenic cell death, we evaluated the release of danger-associated molecular patterns using immunohistochemistry and flow cytometry, as well as an in vivo challenge. Our results showed that the combination of colloidal silver and sodium dichloroacetate is more effective than each treatment alone and that the antitumor mechanism is not through immunogenic cell death. Furthermore, this study can broadly contribute to the development of dichloroacetate-loaded silver nanoparticles and to the design targeted pharmacological formulations to fight melanoma as well as other types of cancer.

9 April 2018 in Biotechnology & Biotechnological Equipment
Verified
Journal Article
Open access
MMMoisés Armides Franco Molina
Moisés Armides Franco Molina
SSSilvia Santana-Krímskaya
Silvia Santana-Krímskaya
ECErika E. Coronado-Cerda
Erika E. Coronado-Cerda
CLCarlos Eduardo Hernández Luna
Carlos Eduardo Hernández Luna
DTDIANA ZARATE TRIVIÑO
DIANA ZARATE TRIVIÑO
CRCristina Rodríguez-Padilla
Cristina Rodríguez-Padilla
IMMUNEPOTENT CRP is a dialyzable leukocyte extract obtained from bovine spleen with immunomodulatory and antitumour properties; therefore, when administrated as an adjuvant therapy for cancer patients, it has increased their survival and quality of life. The bioavailability of any orally administered compound can be reduced due to gastrointestinal enzymes. In this study, we evaluated if IMMUNEPOTENT CRP is resistant to the treatment with different enzymes (proteases, nucleases, polysaccharide-degrading enzymes or lipase), using as parameters for biological activity measurement its in vitro antitumour and antioxidant properties and in vivo the antitumour effect of IMMUNEPOTENT CRP treated with proteinase K. In conclusion, we consider necessary to include the antioxidant and cytotoxic activity on the MCF-7 cancer cell line as parameters for the quantitative determination of biological activity or potency tests for batch release. Additionally, the results showed that different enzymatic treatments do not affect the antitumour and antioxidant activities of IMMUNEPOTENT CRP in vitro, suggesting that this product can be administered orally without any loss of biological activity. Furthermore, IMMUNEPOTENT CRP treatment with proteinase K increases the antitumour activity in vivo.